Needham & Company LLC reissued their buy rating on shares of Dermira, Inc. (NASDAQ:DERM) in a report published on Tuesday morning. The firm currently has a $46.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald began coverage on shares of Dermira in a research note on Thursday, June 22nd. They set an overweight rating and a $45.00 price objective for the company. BidaskClub raised shares of Dermira from a sell rating to a hold rating in a research note on Thursday, June 15th. Mizuho dropped their price objective on shares of Dermira from $42.00 to $40.00 and set a buy rating for the company in a research note on Thursday, May 25th. Finally, Evercore ISI assumed coverage on shares of Dermira in a research note on Thursday, June 29th. They issued an outperform rating and a $48.00 target price for the company. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $43.80.

Dermira (DERM) traded up 1.71% during midday trading on Tuesday, hitting $29.09. The stock had a trading volume of 104,066 shares. The stock has a 50-day moving average price of $28.99 and a 200 day moving average price of $31.12. The firm’s market cap is $1.21 billion. Dermira has a 12-month low of $25.63 and a 12-month high of $38.75.

COPYRIGHT VIOLATION NOTICE: “Needham & Company LLC Reiterates Buy Rating for Dermira, Inc. (DERM)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/07/21/needham-company-llc-reiterates-buy-rating-for-dermira-inc-derm.html.

In other Dermira news, SVP Christopher M. Griffith sold 1,312 shares of Dermira stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $27.07, for a total value of $35,515.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eugene A. Bauer sold 2,500 shares of Dermira stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $30.00, for a total transaction of $75,000.00. The disclosure for this sale can be found here. Insiders sold a total of 16,312 shares of company stock valued at $468,441 over the last ninety days. 13.30% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in Dermira during the first quarter valued at approximately $2,346,000. Platinum Investment Management Ltd. boosted its stake in shares of Dermira by 53.4% in the first quarter. Platinum Investment Management Ltd. now owns 44,800 shares of the biopharmaceutical company’s stock valued at $1,528,000 after buying an additional 15,600 shares in the last quarter. Clough Capital Partners L P boosted its stake in shares of Dermira by 10.5% in the first quarter. Clough Capital Partners L P now owns 254,785 shares of the biopharmaceutical company’s stock valued at $8,691,000 after buying an additional 24,200 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Dermira during the first quarter valued at about $1,364,000. Finally, Endurant Capital Management LP boosted its stake in shares of Dermira by 24.3% in the first quarter. Endurant Capital Management LP now owns 31,188 shares of the biopharmaceutical company’s stock valued at $1,064,000 after buying an additional 6,100 shares in the last quarter. 84.58% of the stock is owned by hedge funds and other institutional investors.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.